



Joseph E. Abboud, Associate

By Electronic Mail  
September 25, 2018

Mike Davis, Esquire  
Chief Counsel for Nominations  
United States Senate Committee on the Judiciary  
Senator Chuck Grassley (R-IA), Chairman  
224 Dirksen Senate Office Building  
Washington, DC 20510

Dear Mr. Davis:

Attached please find materials responsive to the requests for documents contained in Senator Grassley's letter dated September 23, 2018. We reserve the right to provide supplemental documents as necessary.

Sincerely,

A handwritten signature in black ink, appearing to read "Joseph E. Abboud", written in a cursive style.

Joseph E. Abboud  
Attorney for Dr. Christine Blasey Ford

Encl.

cc: Heather Sawyer, Esquire

**Christine Blasey MA, PhD, MS**

Palo Alto, CA

Education

**Master of Science, Epidemiology, 2009**  
**Stanford University School of Medicine**  
**Department of Health Research and Policy**

Specialization: Biostatistics  
GPA 4.0

**Doctor of Philosophy, Psychology, 1996**

**University of Southern California, Rossier School of Education (APA-accredited)**

Specialization: Marriage and Family Therapy, Research Design and Statistics  
Dissertation: Psychometric Development of a Measure of Children's Coping Strategies  
GPA 3.9

**Predoctoral Clinical Psychology Internship, 1994**

**University of Hawai'i at Manoa (APA-accredited)**

**Master of Arts, Clinical Psychology, 1991**

**Pepperdine University, 1991**

Dean's Letter of Commendation  
GPA 4.0

**Bachelor of Arts, Experimental Psychology, 1988**

**University of North Carolina at Chapel Hill**

**High School, 1984**

**Holton-Arms School**

Bethesda, Maryland

Current Employment

Current      **Professor, PGSP-Stanford University Consortium for Clinical Psychology**  
**Stanford University School of Medicine Department of Psychiatry and Palo Alto**  
**University**

Director of Student Research Competence.

Teach Statistics, Research Methods, Psychometrics, Dissertation Preparation Seminar,  
Advanced Statistics and Scientific Writing.

Mentor students and serve on 10-15 Dissertation Committees per year. Common student-  
led research areas include Evidence-based treatments for Depression, Anxiety, ADHD,  
Autism Spectrum and other Developmental Disorders, Trauma and other illnesses in  
Veteran populations

Golden Apple Award, Winner 2012 and 2018

**Research Psychologist and Biostatistician, Stanford University School of Medicine  
Department of Psychiatry**

Design studies and conduct statistical analyses supporting faculty research across child and adult psychiatry. Statistical expertise in centering, interaction effects, mediation and moderation. Studies focus on child and adulthood psychiatric conditions, their etiologies and effective treatments. Provide statistical expertise to faculty in other departments within the School of Medicine (e.g., cardiology)

**Prior Employment**

- 2012-4, 2017 **Consulting Biostatistician**, Titan Pharmaceuticals, San Francisco, CA  
Conduct statistical analyses regarding the efficacy of novel treatments for opioid abuse disorders.
- 2012-4, 2017 **Consulting Biostatistician**, Brain Resource, Sydney, Australia  
Conduct statistical analyses regarding the putative psychological and biological markers of treatment response to ADD and Antidepressant medications.
- 2010-2012 **Director, Corcept Therapeutics**
- 2005-2012 **Associate Director, Statistician, Corcept Therapeutics**  
  
Led statistical activities of Phase 3 program for development of new medicines. Designed and constructed databases, chose analytic models, wrote statistical programs, co-authored Statistical Analysis Plans, co-authored Clinical Study reports (CSR), and co-wrote manuscripts for scientific publications. Presented at professional meetings including NCDEU and APA.
- 1999-current **Research Psychologist, Stanford University**  
  
Provided data analytic and research design support for faculty and trainees in the Department of Psychiatry & Behavioral Sciences. Received formal mentoring from Helena C. Kraemer. Co-authored manuscripts, presented at professional conferences, taught statistics courses for MD and PhD postdocs and research fellows, provided training courses in SPSS. Taught statistics courses for 3 years in Child Psychiatry postdoctoral fellowship program and in the Stanford-PGSP Consortium.
- 1999-2001 **Biostatistician, The Children's Health Council**  
  
Designed and conducted program evaluations. Provided project management and supervised Research Assistants in their research projects.

1995-98

**Visiting Professor, Pepperdine University**

Taught full time (10 classes per year) in the undergraduate and graduate psychology programs. Courses Taught: Psych 101 (small class and large lecture hall), Introductory Statistics, Intermediate Statistics, Computer Applications in Statistics, Psychological Testing and Assessment, Developmental Psychology, Personality Theory, Family Therapy. Nominee, Tyler Teacher of the Year Award, 1996.

Computer Skills

SPSS

QROC (signal detection)

SAS – Level 4

Statistical Reviewer

Multiple psychiatry and statistics journals

Sample of Awards and Invited Talks

- 2018           Invited Statistics Mentor, NIH-American Psychiatric Association Annual Meeting, New York
- 2017           Invited Statistics Mentor, NIH-American Psychiatric Association Annual Meeting, San Diego
- 2018           Golden Apple Teaching Award in Statistics, PGSP-Stanford Psy.D Consortium
- 2012           Golden Apple Teaching Award in Statistics, PGSP-Stanford Psy.D Consortium
- 2014-5         Roundtable Lead Discussant, Statistical Analysis in Industry-FDA Interactions. American Statistical Association Annual FDA meeting with Industry and Academic Statisticians. Washington, DC
- 1997           Ron Tyler Teaching Award Finalist, Pepperdine University

Book and Book Chapters

Kraemer HC and **Blasey C.** (2015) *How Many Subjects?* Los Angeles: Sage Publications.

Blasey C, DeBattista C, Belanoff J, Schatzberg A (2010). Psychopharmacology. In Koocher G (Editor), Psychologists Desk Reference.

## **\*\*Sample Peer Reviewed Publications**

Williams N, Heiferts B, **Blasey C**, Sudheimer K, Schatzberg A. (August, 2018). Opioid Receptor Antagonism Attenuates the Antidepressant Effects of Ketamine. *American Journal of Psychiatry*.

Arnold BA, **Blasey CB**, Rush AJ. Beyond symptom reduction: Poor Quality of Life, Daily Functioning, and Life Satisfaction issues persist (*In preparation*).

Avery T, **Blasey C**, Rosen C, Bayley P. Psychological Flexibility and Set-Shifting Among Veterans Participating in a Yoga Program: A Pilot Study. *Mil Med*. 2018 Mar 26.

Elliott GR, **Blasey C**, Rekshan W, Rush AJ, Palmer DM, Clarke S, Kohn M, Kaplan C, Gordon E. Cognitive Testing to Identify Children With ADHD Who Do and Do Not Respond to Methylphenidate. *J Atten Disord*. 2017 Dec;21(14):1151-1160.

Cohen JM, **Blasey C**, Barr Taylor C, Weiss BJ, Newman MG Anxiety and Related Disorders and Concealment in Sexual Minority Young Adults. *Behav Ther*. 2016 Jan;47(1):91-101.

Korgaonkar MS, Rekshan W, Gordon E, Rush AJ, Williams LM, **Blasey C**, Grieve SM. Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder. 2015 Dec 3; 2 (1):37-45.

Arnold BA, **Blasey C**, Williams LM, Palmer DM, Rekshan W, Schatzberg AF, Etkin A, Kulkarni J, Luther JF, Rush AJ. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. *Am J Psychiatry*. 2015 Aug 1; 172 (8):743-50.

Abbasi F, **Blasey C**, Feldman D, Caulfield MP, Hantash FM, Reaven GM. Low circulating 25-hydroxyvitamin D concentrations are associated with defects in insulin action and insulin secretion in persons with prediabetes. *J Nutr*. 2015 Apr; 145 (4):714-9.

Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkar A, Chavoustie S, **Blasey C**, Sigmon S, Beebe KL. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. *Addiction*. 2013 Dec; 108 (12):2141-9.

**Blasey C**, McLain C, Belanoff J. (2013). Trough Plasma Concentrations of Mifepristone Correlate with Psychotic Symptom Reductions: A Review of Three Randomized Clinical Trials. *Current Psychiatry Reviews*.

**Blasey C**, Belanoff J, DeBattista C, Schatzberg A (2013). Adult Psychopharmacology. In Koocher, Norcross, Hill (Eds). *Psychologist's Desk Reference*. Oxford University Press.

Steidtmann D, Manber R, **Blasey C**, Markowitz JC, Klein DN, Rothbaum BO, Thase ME, Kocsis JH, Arnold BA. Detecting Critical Decision Points in Psychotherapy and Psychotherapy + Medication for Chronic Depression. *J Consult Clin Psychol*. 2013 Jun 10.

Arnow BA, Steidtmann D, **Blasey C**, Manber R, Constantino MJ, Klein DN, Markowitz JC, Rothbaum BO, Thase ME, Fisher AJ, Kocsis JH. The relationship between the therapeutic alliance and treatment outcome in two distinct psychotherapies for chronic depression. *J Consult Clin Psychol*. 2013 Aug; 81(4):627-38.

Abbasi F, **Blasey C**, Reaven GM. Cardiometabolic risk factors and obesity: does it matter whether BMI or waist circumference is the index of obesity? *Am J Clin Nutr*. 2013 Sep; 98(3):637-40.

Bhat SL, Abbasi FA, **Blasey C**, Reaven GM, Kim SH. Beyond fasting plasma glucose: The association between coronary heart disease risk and postprandial glucose, postprandial insulin and insulin resistance in healthy, nondiabetic adults. *Metabolism*. 2013 Sep; 62(9):1223-6.

Bhat S, Abbasi F, **Blasey C**, Reaven G, Kim Sh. Plasma glucose and insulin responses to mixed meals: impaired fasting glucose re-visited. *Diab Vasc Dis Res*. 2011 Oct; 8(4):271-5.

Andrade C, Shaikh SA, Narayan L, **Blasey C**, Belanoff J. Administration of a selective glucocorticoid antagonist attenuates electroconvulsive shock-induced retrograde amnesia. *J Neural Transm*. 2012 Mar; 119(3):337-44.

**Blasey C**, Block T, Belanoff JK, Roe RL. Efficacy and Safety of Mifepristone for the treatment of Psychotic Depression. *Journal of Clinical Psychopharmacology*, 2011 Aug; 31(4): 436-440.

Asagami T, Belanoff JK, Azuma J, **Blasey C**, Tsao P. Selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice. *Journal of Nutrition and Metabolism*, 2011.

Arnow BA, **Blasey CM**, Hunkeler EM, Lee J, Hayward C. Does Gender Moderate the Relationship Between Childhood Maltreatment and Adult Depression? *Child Maltreat*. 2011 Jul 4.

Arnow BA, **Blasey CM**, Constantino MJ, Robinson R, Hunkeler E, Lee J, Fireman B, Khaylis A, Feiner L, Hayward C. Catastrophizing, depression and pain-related disability. *Gen Hosp Psychiatry*. 2011 Mar-Apr; 33(2):150-6.

Belanoff JK, **Blasey CM**, Clark RD, Roe RL. Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats. *Eur J Pharmacol*. 2011 Mar 25; 655(1-3):117-20.

Belanoff JK, **Blasey CM**, Clark RD, Roe RL. Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain. *Diabetes Obes Metab*. 2010 Jun; 12(6):545-7.

Parker KJ, Kenna HA, Zeitzer JM, Keller J, **Blasey CM**, Amico JA, Schatzberg AF. Preliminary evidence that plasma oxytocin levels are elevated in major depression. *Psychiatry Res*. 2010 Jul 30; 178(2):359-62.

**Blasey CM**, Debattista C, Roe R, Block T, Belanoff JK. A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. *Contemporary Clinical Trials*. 2009, 30(4):284-8.

Gross C, **Blasey CM**, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. *Obesity (Silver Spring)*. 2010 Dec; 18(12):2295-300.

Gross C, **Blasey C**, Allen K, Block T, Belanoff J. Mifepristone treatment of olanzapine-induced weight gain in healthy men. *Advances in Therapy*, 2009 (20):576-586.

Reaven GM, Lieberman JA, Sethuraman G, Kraemer H, Davis JM, **Blasey C**, Tsuang MT, Schatzberg AF. (2009) In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. *J Psychiatr Res*. 2009 Mar 6.

Arnow BA, **Blasey CM**, Lee J, Fireman B, Hunkeler EM, Dea R, Robinson R, Hayward C. Relationships among depression, chronic pain, chronic disabling pain, and medical costs. *Psychiatric Services*. 2009 Mar; 60(3):344-50.

Butler LD, Koopman C, Azarow J, **Blasey CM**, Magdalene JC, DiMiceli S, Seagraves DA, Hastings TA, Chen XH, Garlan RW, Kraemer HC, Spiegel D Psychosocial predictors of resilience after the September 11, 2001 terrorist attacks. *J Nerv Ment Dis*. 2009 Apr; 197(4):266-73.

Manber R, **Blasey C**, Allen JJ Depression symptoms during pregnancy. *Archives of Womens Mental Health*. 2008; 11(1):43-8.

Butler LD, Waelde LC, Hastings TA, Chen XH, Symons B, Marshall J, Kaufman A, Nagy TF, **Blasey CM**, Seibert EO, Spiegel D. Meditation with yoga, group therapy with hypnosis, and psychoeducation for long-term depressed mood: a randomized pilot trial. *Journal of Clinical Psychology*, 2008 Jul; 64(7):806-20.

Arnow BA, **Blasey C**, Manber R, Constantino MJ, Markowitz JC, Klein DN, Thase ME, Kocsis JH, Rush AJ. Dropouts versus completers among chronically depressed outpatients. *Journal of Affective Disorders*. 2007 Jan;97(1-3):197-202.

Classen CC, Kraemer HC, **Blasey C**, Giese-Davis J, Koopman C, Palesh OG, Atkinson A, Dimiceli S, Stonisch-Riggs G, Westendorp J, Morrow GR, Spiegel D. Supportive-expressive group therapy for primary breast cancer patients: a randomized prospective multicenter trial. *Psychooncology*. 2008 May;17(5):438-47.

Arnow B, **Blasey C**, Manber R, Constantino M, Hayward C. Dropouts Versus Completers Among Chronically Depressed Outpatients. *Journal of Affective Disorders*. 2006.

Arnow B, Hunkeler, E. **Blasey C**, Hayward C. Comorbid Depression, Chronic Pain, and Disability in Primary Care. *Psychosomatic Medicine*, 2006, 68:262-268.

Doumas D, **Blasey C**, Thacker C. Attrition from Alcohol and Drug Outpatient Treatment: Psychological Distress and Interpersonal Problems as Indicators. *Alcoholism Treatment Quarterly*, 2006 23 (4), 55-67.

DeBattista C, Belanoff J, Glass S, Khan A, Horne R, **Blasey C**, Carpenter L, Alva G. Mifepristone versus Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression. *Biological Psychiatry*, 2006.

Beebe K, Block T, DeBattista C, **Blasey C**, Belanoff J. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. *Behavioural Brain Research*, 2006, 171 (2), 225-9.

Constantino M, Arnow B, **Blasey C**, Agras S. The association between patient characteristics and the therapeutic alliance in cognitive-behavioral and interpersonal therapy in bulimia. *Journal of Consulting and Clinical Psychology*, 2005; 73(2): 203-211

Manber R, **Blasey C**. Arnow B, Markowitz J, Thase M, Rush A, Dowling F, Koscis J, Trivedi M, Keller, M. Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries, *Journal of Psychiatric Research*, 2005, 39(5), 481-8.

Belanoff J, Sund B, Koopman C, **Blasey C**, Flamm J, Schatzberg A, Spiegel D. A randomized trial of the efficacy of group psychotherapy in changing viral load and CD4 counts in individuals living with HIV infection. *International Journal of Psychiatry in Medicine*, 2005, 35(4), 349-362.

Lee T, **Blasey C**, Dyer-Friedman J, Glaser B, Reiss AL, Eliez S. From Research to Practice: Teacher and Pediatrician Awareness of Phenotypic Traits in Neurogenetic Syndromes. *American Journal of Mental Retardation*. 2005, 110(2), 100-106.

Kraemer HC, **Blasey CM**. Centring in regression analyses: a strategy to prevent errors in statistical inference. *International Journal Methods Psychiatric Research*. 2004, 13(3):141-51.

Saxena K, **Blasey C**. Research Methodology in Clinical Trials. In Steiner, H (Ed.) Handbook of mental health interventions in children and adolescents: An integrated developmental approach. San Francisco: Jossey Bass.

Fleming S, **Blasey C**, Schatzberg A. Neuropsychological correlates of psychotic features in major depressive disorders: A review and meta-analysis. *Journal of Psychiatric Research*, 2004, 38(1), 27-35.

Manber R, Schnyer RN, Allen JJ, Rush AJ, **Blasey CM**. Acupuncture: A promising treatment for depression during pregnancy. *Journal of Affective Disorders*. 2004 Nov 15, 83(1):89-95.

Arnow BA, Manber R, **Blasey C**, Klein DN, Blalock JA, Markowitz JC, Rothbaum BO, Rush AJ, Thase ME, Riso LP, Vivian D, McCullough JP Jr, Keller MB. Therapeutic reactance as a predictor of outcome in the treatment of chronic depression. *Journal of Consulting and Clinical Psychology*. 2003 Dec;71(6):1025-35.

Jutte D, Burgos A, Mendoza M, **Blasey Ford C**, Huffman LC. Use of the Pediatric Symptom Checklist in a Low-Income, Mexican American Population *Archives Pediatric and Adolescent Medicine*. 2003;157:1169-1176.

Piggot J, Kwon H, Mobbs D, **Blasey C**, Lotspeich L, Menon V, Bookheimer S, Reiss AL. Emotional attribution in high-functioning individuals with autistic spectrum disorder: a functional imaging study. *Journal of American Academy of Child and Adolescent Psychiatry*. 2004 Apr;43(4):473-80.

Manber R, Arnow B, **Blasey C**, and others. Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication. *Psychological Medicine*. 2003 May;33(4):693-702.



Kesler SR, Adams HF, **Blasey CM**, Bigler ED. Premorbid intellectual functioning, education, and brain size in traumatic brain injury: an investigation of the cognitive reserve hypothesis. *Applied Neuropsychology*. 2003;10(3):153-62

Shaw RJ, Palmer L, **Blasey C**, Sarwal M. A typology of non-adherence in pediatric renal transplant recipients. *Pediatric Transplant*. 2003 Dec;7(6):489-93.

Chang KD, **Blasey CM**, Ketter TA, Steiner H. Temperament characteristics of child and adolescent bipolar offspring. *Journal of Affective Disorders*. 2003 Oct; 77(1):11-9.

Kesler SR, **Blasey CM**, Brown WE, Yankowitz J, Zeng SM, Bender BG, Reiss AL. Effects of X-monosomy and X-linked imprinting on superior temporal gyrus morphology in Turner syndrome. *Biological Psychiatry*. 2003 Sep 15; 54(6):636-46.

Chang KD, Dienes K, **Blasey C**, Adleman N, Ketter T, Steiner H. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. *Journal of Clinical Psychiatry*, 2003, Aug; 64(8):936-42.

Johnston C, Hessel D, **Blasey C**, Eliez S, Erba H, Dyer-Friedman J, Glaser B, Reiss AL. Factors associated with parenting stress in mothers of children with fragile X syndrome. *Journal of Developmental and Behavioral Pediatrics*. 2003 Aug; 24(4):267-75.

Glaser B, Mumme D, **Blasey C**, Morris M, Dahoun S, Antonarakis S, Reiss A, Eliez S. Language skills in children with velocardial facial syndrome (deletion 22q11.2). *Journal of Pediatrics*. 2002 Jun; 140(6), 61-75.

Adleman N, Menon V, **Blasey C**, White C, Reiss A. A developmental fMRI Study of the Stroop Color-Word Task. *Neuroimage*. 2002. Jul; 16 (1): 61-75.

Eliez, S, Blasey C, White, C, Menon, V, Reiss, A. Functional brain imaging study of mathematical reasoning abilities in velocardial facial syndrome (del22q11.2). *Genet Med*. 2001 Jan-Feb; 3(1):49-55.

Yang TT, Menon V, Eliez S, **Blasey C**, Gotlib I, Reiss A. Amygdalar activation associated with positive and negative facial expressions. *Neuroreport: For Rapid Communication of Neuroscience Research*, Vol 13(14), Oct 2002, 1737-1741.

Marks AS, Nichols M, **Blasey C**, Huffman, L. Girls with ADHD and associated behavioral problems: Patterns of comorbidity. *North American Journal of Psychology* Vol 4(3), 2002, 321-332.

Hessel D, Glaser B, Dyer-Friedman J, **Blasey C**. Cortisol and behavior in fragile X syndrome. *Psychoneuroendocrinology*, Vol 27(7), Oct 2002, 855-872.

Dienes KA, Chang KD, **Blasey CM**, Steiner H. Characterization of children of bipolar parents by parent report CBCL. *Journal of Psychiatric Research* Vol 36(5), Sep-Oct 2002, 337-346.

Huffman L, Koopman C, **Blasey C**, Hill K. A program evaluation strategy in a community-based behavioral health and education services agency for children and families. *Journal of Applied Behavioral Science* Vol 38(2), Jun 2002, 191-215.

Feinstein C, Eliez S, **Blasey** C, Reiss A. Psychiatric disorders and behavioral problems in children with velocardiofacial syndrome: Usefulness as phenotypic indicators of schizophrenic risk. *Biological Psychiatry* Vol 51(4), Feb 2002, 312-318.

Chang K, **Blasey** C, Ketter T, Steiner H. Family environment of children and adolescents with bipolar parents. *Bipolar Disorders* Apr 2001, 73-78.

Eliez S, **Blasey** C, Chromosome 22q11 deletion and brain structure. *British Journal of Psychiatry* Vol 179(3), Sep 2001, 270.

Eliez S, **Blasey** C, Freund L, Reiss A. Brain anatomy, gender and IQ in children and adolescents with fragile X syndrome. *Brain* Vol 124(8), Aug 2001, 1610-1618.

Eliez S, **Blasey** C, Schmitt E. Velocardiofacial syndrome: Are structural changes in the temporal and mesial temporal regions related to schizophrenia? *American Journal of Psychiatry* Vol 158(3), Mar 2001, 447-453.cc

Sample of Professional Presentations (not updated, please refer to peer reviewed publications)

Arnow, B., Manber, R., & **Blasey**, C. (2002, November). Does reactance level predict outcome in medication, cognitive behavioral analysis system of psychotherapy or combined treatment for chronic depression? (R. Manber, Chair). Symposium presented at the 36th annual meeting of the Association for the Advancement of Behavior Therapy, Reno.

Manber, R., Arnow, B., & **Blasey**, C. (2002, November). Patient's skill acquisition and response to treatment (R. Manber, Chair). Symposium presented at the 36th annual meeting of the Association for the Advancement of Behavior Therapy, Reno.

Hunkeler, E.M., Arnow, B., Robinson, R., Lee, J., **Blasey**, C., & Fireman, B. Prevalence and characteristics of primary care patients with depression and chronic pain. (2002, December). Poster presented at the 41st annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.

Arnow, B.A., Hunkeler, E.M., **Blasey**, C., Fireman, B., Lee, J., Robinson, R., & Hayward, C. (2003, May). Prevalence and characteristics of patients with depression and/or chronic pain (David K. Gittelman, Chair). Symposium presented at the 156th annual meeting of the American Psychiatric Association, San Francisco.

Hunkeler, E.M., Arnow, B.A., Lee, J., **Blasey**, C., Fireman, B., Robinson, R.L., & Dea, R. (2004, May). Major depressive disorder and comorbid chronic pain, a costly condition. Poster presented at the 157th annual meeting of the American Psychiatric Association, New York.

**Blasey**, C., Lee, J., Hayward, C., Hunkeler, E., Constantino, M., Fireman, B., Robinson, R., Dea, R., & Arnow, B.A. (2004, July). Comorbidity of depression and pain among primary care patients. Paper presented at the 112th meeting of the American Psychological Association, Honolulu, Hawaii.

Arnow, B.A., Treatman, C., & **Blasey**, C. (2004, November). Noncompleters in clinical trials: Implications for research and treatment. Paper presented at the meeting of the North American Chapter of the Society of Psychotherapy Research, Springdale, Utah.

Arnow, B.A., **Blasey**, C., Manber, R., Markowitz, J.C., Klein, D.N., & Kocsis, J.H. (2010, June). Early therapeutic alliance and outcome in CBASP and BSP: Results from the REVAMP Trial. Paper presented at the 41st Annual Meeting of the Society for Psychotherapy Research, Asilomar, CA.

Arnow, B.A., **Blasey**, C., Steidtmann, D., & Manber, R. (2011, June). Cognitive behavioral analysis system of psychotherapy with and without medication for chronic depression: Is there an acute phase triage point? Importance of early response for treatment outcome in different mental health care settings (Bernd Puschner, Moderator). Symposium presented at the 42nd Annual Meeting of the Society for Psychotherapy Research, Berne, Switzerland.

Steidtmann, D., Arnow, B., **Blasey**, C., & Manber, R. (2011, September). Do patient's pre-treatment beliefs about illness causes and preference for treatment modality moderate therapeutic alliance quality and treatment outcome in two types of psychotherapy? Paper presented at the North American Society for Psychotherapy Research, Banff, Canada.

#### Personal Interests and Hobbies

Surfing, Surf travel (Hawai'i, Costa Rica, South Pacific Islands, French Polynesia), Oceanography, Hawai'ian and Tahitian Culture, Spanish Language, College Athletics, AAU Youth Basketball, Palo Alto Youth Soccer

Touch to return to call 17:10



WaPo

last seen today at 9:23 AM



Fri, Jul 6

🔒 Messages to this chat and calls are now secured with end-to-end encryption. Tap for more info.

Potential Supreme Court nominee with assistance from his friend assaulted me in mid 1980s in Maryland. Have therapy records talking about it. Feel like I shouldn't be quiet but not willing to put family in DC and CA through a lot of stress

10:26 AM ✓✓

Brett Kavanaugh with Mark Judge and a bystander named PJ.

11:47 AM ✓✓

Tue, Jul 10

Been advised to contact senators or NYT. Haven't heard back from WaPo

8:03 AM ✓✓

I will get you in touch with reporter

9:21 AM



July 30, 2018

**CONFIDENTIAL**

Senator Dianne Feinstein

Dear Senator Feinstein:

I am writing with information relevant in evaluating the current nominee to the Supreme Court. As a constituent, I expect that you will maintain this as confidential until we have further opportunity to speak.

Brett Kavanaugh physically and sexually assaulted me during High School in the early 1980's. He conducted these acts with the assistance of his close friend, Mark G. Judge. Both were 1-2 years older than me and students at a local private school. The assault occurred in a suburban Maryland area home at a gathering that included me and 4 others. Kavanaugh physically pushed me into a bedroom as I was headed for a bathroom up a short stairwell from the living room. They locked the door and played loud music, precluding any successful attempts to yell for help. Kavanaugh was on top of me while laughing with Judge, who periodically jumped onto Kavanaugh. They both laughed as Kavanaugh tried to disrobe me in their highly inebriated state. With Kavanaugh's hand over my mouth, I feared he may inadvertently kill me. From across the room, a very drunken Judge said mixed words to Kavanaugh ranging from "go for it" to "stop". At one point when Judge jumped onto the bed, the weight on me was substantial. The pile toppled, and the two scrapped with each other. After a few attempts to get away, I was able to take this opportune moment to get up and run across to a hallway bathroom. I locked the bathroom door behind me. Both loudly stumbled down the stairwell, at which point other persons at the house were talking with them. I exited the bathroom, ran outside of the house and went home.

I have not knowingly seen Kavanaugh since the assault. I did see Mark Judge once at the Potomac Village Safeway, where he was extremely uncomfortable seeing me.

I have received medical treatment regarding the assault. On July 6, I notified my local government representative to ask them how to proceed with sharing this information. It is upsetting to discuss sexual assault and its repercussions, yet I felt guilty and compelled as a citizen about the idea of not saying anything.

I am available to speak further should you wish to discuss. I am currently vacationing in the mid-Atlantic until August 7<sup>th</sup> and will be in California after August 10<sup>th</sup>.

In Confidence,

Christine Blasey

Palo Alto, California

██████████

By Electronic Mail  
September 18, 2018

The Honorable Charles E. Grassley  
Chairman, Committee on the Judiciary  
United States Senate  
135 Hart Senate Office Building  
Washington, D.C. 20510

Dear Senator Grassley:

Thank you for reaching out yesterday afternoon. Dr. Christine Blasey Ford looks forward to working with you and the Committee.

As you know, earlier this summer, Dr. Ford sought to tell her story, in confidence, so that lawmakers would have a fuller understanding of Brett Kavanaugh's character and history. Only after the details of her experience were leaked did Dr. Ford make the reluctant decision to come forward publicly.

In the 36 hours since her name became public, Dr. Ford has received a stunning amount of support from her community and from fellow citizens across our country. At the same time, however, her worst fears have materialized. She has been the target of vicious harassment and even death threats. As a result of these kind of threats, her family was forced to relocate out of their home. Her email has been hacked, and she has been impersonated online.


While Dr. Ford's life was being turned upside down, you and your staff scheduled a public hearing for her to testify at the same table as Judge Kavanaugh in front of two dozen U.S. Senators on national television to relive this traumatic and harrowing incident. The hearing was scheduled for six short days from today and would include interrogation by Senators who appear to have made up their minds that she is "mistaken" and "mixed up." While no sexual assault survivor should be subjected to such an ordeal, Dr. Ford wants to cooperate with the Committee and with law enforcement officials.

As the Judiciary Committee has recognized and done before, an FBI investigation of the incident should be the first step in addressing her allegations. A full investigation by law enforcement officials will ensure that the crucial facts and witnesses in this matter are assessed in a non-partisan manner, and that the Committee is fully informed before conducting any hearing or making any decisions.

The Honorable Charles E. Grassley  
Chairman, Committee on the Judiciary  
September 18, 2018  
Page 2

We would welcome the opportunity to talk with you and Ranking Member Feinstein to discuss reasonable steps as to how Dr. Ford can cooperate while also taking care of her own health and security.

Sincerely,



Debra S. Katz



Lisa J. Banks  
Attorneys for Dr. Christine Blasey Ford

cc: The Honorable Dianne Feinstein  
Ranking Member, Committee on the Judiciary

September 22, 2018

Dear Senator Grassley:

There has been a lot of back and forth between your staff and my counsel, and I appreciate the chance to communicate with you directly. I kindly ask you to use your best discretion regarding this personal letter.

When I first learned that Brett Kavanaugh was on the short-list of nominees to fill a Supreme Court vacancy, prior to the President's selection among a list of what seemed to me as similarly-qualified candidates, I contacted my Congressperson's office in an attempt to provide information that could be useful to you and the President when making the selection from among a list of candidates. The decision to first report the assault to my Congresswoman, Rep. Anna Eshoo, was a very difficult one, but I felt that this was something that a citizen couldn't NOT do. I felt agony yet urgency and a civic duty to let it be known, in a confidential manner, prior to the nominee being selected. While it was difficult, I was able to share my information with two contacts during the period between the short list announcement and Mr. Kavanaugh's selection.

Mr. Kavanaugh's actions, while many years ago, were serious and have had a lasting impact on my life. I thought that knowledge of his actions could be useful for you and those in charge of choosing among the various candidates. My original intent was first and foremost to be a helpful citizen – in a confidential way that would minimize collateral damage to all families and friends involved.

I then took the step of sending a confidential letter to one of my Senators, Ranking Member Feinstein, and I understand that you have a copy of that letter. I am certainly prepared to repeat the facts in the letter and to provide further facts under oath at a hearing. I would welcome the opportunity to meet with you and other Senators directly, person to person, to tell you what occurred. I will answer any questions you have. I hope that we can find such a setting and that you will understand that I have one motivation in coming forward – to tell the truth about what Mr. Kavanaugh and his friend Mark Judge did to me. My sincere desire is to be helpful to persons making the decision.

In addition to talking with you and other Senators directly, I have asked my lawyers to continue discussions with your staff about the conditions you have proposed. As I am not a lawyer or a Senator, I am relying on them and you to ensure that the Committee will agree to conditions that will allow me to testify in a fair setting that won't disrupt families and become a media TV show. While the nationwide outpouring of love has been heartwarming, I am spending considerable time managing death threats, avoiding people following me on freeways, and disconcerting media intrusion, including swarms of vans at my home and unauthorized persons entering my classroom and medical settings where I work. I have received an inordinate number of requests to appear on major TV shows to elucidate further information, to which I have not responded. My goal is to return soon to my workplace, once it is deemed safe for me and importantly, for students. Currently, my family has physically relocated and have divided up separately on many nights with the tremendous help of friends in the broader community. Through gracious persons here and across the country, we have been able to afford hiring security. While I am frightened, please know, my fear will not hold me back from testifying and



you will be provided with answers to all of your questions. I ask for fair and respectful treatment.

Kind regards,

Christine Blasey

## DECLARATION OF RUSSELL FORD

I, Russell Ford, hereby state that I am over eighteen (18) years of age, am competent to testify, and have personal knowledge of the following facts:

1. I have a Master of Science degree and a Doctor of Philosophy degree in mechanical engineering from Stanford University.
2. I have been married to Christine Blasey Ford since June 2002. We have two children.
3. The first time I learned that Christine had any experience with sexual assault was around the time we got married, although she did not provide any details.
4. Christine shared the details of the sexual assault during a couple's therapy session in 2012. She said that in high school she had been trapped in a room and physically restrained by one boy who was molesting her while another boy watched. She said she was eventually able to escape before she was raped, but that the experience was very traumatic because she felt like she had no control and was physically dominated.
5. I remember her saying that the attacker's name was Brett Kavanaugh, that he was a successful lawyer who had grown up in Christine's home town, and that he was well-known in the Washington, D.C. community.
6. In the years following the therapy session, we spoke a number of times about how the assault affected her.
7. The next time she mentioned that Mr. Kavanaugh was the person who sexually assaulted her was when President Trump was in the process of selecting his first nominee for the Supreme Court. Before the President had announced that Judge Neil Gorsuch was the nominee, I remember Christine saying she was afraid the President might nominate Mr. Kavanaugh.


8. These conversations about Mr. Kavanaugh started again shortly after Justice Anthony Kennedy announced his resignation and the media began reporting that Mr. Kavanaugh was on the President's "short list."

9. Christine was very conflicted about whether she should speak publicly about what Mr. Kavanaugh had done to her, as she knew it would be emotionally trying for her to relive this traumatic experience in her life and hard on our family to deal with the inevitable public reaction. However, in the end she believed her civic duty required her to speak out.

10. In our 16 years of marriage I have always known Christine to be a truthful person of great integrity. I am proud of her for her bravery and courage.

I solemnly swear or affirm under the penalties of perjury that the matters set forth in this Declaration are true and correct to the best of my personal knowledge, information, and belief.

Executed on this 25<sup>th</sup> day of September, 2018.



Russell Ford

## DECLARATION OF KEITH KOEGLER

I, Keith Koegler, hereby state that I am over eighteen (18) years of age, am competent to testify, and have personal knowledge of the following facts:

1. I graduated from Amherst College in 1992 with a Bachelor's Degree in History. I earned my Juris Doctor degree from Vanderbilt Law School in 1997.

2. I have known Christine Blasey Ford and her husband, Russell Ford, for more than five years, and consider them close friends.

3. We met when I was coaching their son's baseball team. Our children are close friends and have played sports together for years. I have spent a lot of time with Christine and her husband traveling to and attending our kids' games. Our families have also gone on vacation together.

4. The first time I learned that Christine had experienced sexual assault was in early summer of 2016. We were standing together in a public place watching our children play together.

5. I remember the timing of the conversation because it was shortly after Stanford University student Brock Turner was sentenced for felony sexual assault after raping an unconscious woman on Stanford's campus. There was a common public perception that the judge gave Mr. Turner too light of a sentence.

6. Christine expressed anger at Mr. Turner's lenient sentence, stating that she was particularly bothered by it because she was assaulted in high school by a man who was now a federal judge in Washington, D.C.

7. Christine did not mention the assault to me again until June 29, 2018, two days after Justice Anthony Kennedy announced his resignation from the Supreme Court of the United States.

8. On June 29, 2018, she wrote me an email in which she stated that the person who assaulted her in high school was the President's "favorite for SCOTUS."

9. On June 29, 2018, I responded with an email in which I stated:

"I remember you telling me about him, but I don't remember his name. Do you mind telling me so I can read about him?"


10. Christine responded by email and stated:

"Brett Kavanaugh"

11. In all of my dealings with Christine I have known her to be a serious and honorable person.

I solemnly swear or affirm under the penalties of perjury that the matters set forth in this Declaration are true and correct to the best of my personal knowledge, information, and belief.

Executed on this 24<sup>th</sup> day of September, 2018.

  
\_\_\_\_\_  
Keith Koegler

## DECLARATION OF ADELA GILDO-MAZZON

I, Adela Gildo-Mazzon, hereby state that I am over eighteen (18) years of age, am competent to testify, and have personal knowledge of the following facts:

1. I have known Christine Blasey Ford for over 10 years and consider her to be a good friend. Our children attended elementary school together.
2. In June of 2013, Christine and I met at a restaurant that was then called Pizzeria Venti Mountain View, located at 1390 Pear Avenue, Mountain View, California.
3. I remembered the year of the meeting because I was temporarily working in the South Bay at that time. I would pass Mountain View on my way home, so that restaurant was a convenient place to arrange a meeting. I believe this was the only time I ever went to this restaurant. I also have a receipt from the restaurant from that meal.
4. During our meal, Christine was visibly upset, so I asked her what was going on.
5. Christine told me she had been having a hard day because she was thinking about an assault she experienced when she was much younger. She said that she had been almost raped by someone who was now a federal judge. She told me she had been trapped in a room with two drunken guys, and that she then escaped, ran away, and hid.
6. Christine said it was a scary situation and that it has impacted her life ever since.
7. The last time I saw Christine was in May 2018.
8. After reading her first person account of the assault in *The Washington Post* on September 16, 2018, I contacted Christine's lawyers to advise them that she had told me about this assault in 2013.

I solemnly swear or affirm under the penalties of perjury that the matters set forth in this Declaration are true and correct to the best of my personal knowledge, information, and belief.

Executed on this 24<sup>th</sup> day of September, 2018.

A handwritten signature in black ink, appearing to read 'Adela Gildo-Mazzon', written over a horizontal line.

Adela Gildo-Mazzon


## DECLARATION OF REBECCA WHITE

I, Rebecca White, hereby state that I am over eighteen (18) years of age, am competent to testify, and have personal knowledge of the following facts:

1. I have been friends with Christine Blasey Ford for more than six years. We are neighbors and our kids went to the same elementary school.
2. In 2017, I was walking my dog and Christine was outside of her house. I stopped to speak with her, and she told me she had read a recent social media post I had written about my own experience with sexual assault.
3. She then told me that when she was a young teen, she had been sexually assaulted by an older teen. I remember her saying that her assailant was now a federal judge.
4. I have always known Christine to be a trustworthy and honest person.

I solemnly swear or affirm under the penalties of perjury that the matters set forth in this Declaration are true and correct to the best of my personal knowledge, information, and belief.

Executed on this 25 day of Sept, 2018.

  
\_\_\_\_\_  
Rebecca White